Caris Life Sciences Inc (CAI)

Currency in USD
21.80
-0.38(-1.71%)
Closed·
21.800.00(0.00%)
·
CAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21.4522.43
52 wk Range
14.1942.50
Key Statistics
Prev. Close
21.8
Open
22.26
Day's Range
21.45-22.43
52 wk Range
14.19-42.5
Volume
3.87M
Average Volume (3m)
3.64M
1-Year Change
-40.274%
Book Value / Share
2.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
27.00
Upside
+23.85%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings downwards for the upcoming period

Caris Life Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 27.00
(+23.85% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Buy28.00+28.44%-New CoverageJul 30, 2026
Baird
Buy23.00+5.50%22.00MaintainJul 13, 2026
BTIG
Buy32.00+46.79%-MaintainJul 02, 2026
Wolfe Research
Hold---New CoverageJun 01, 2026
Baird
Buy22.00+0.92%28.00MaintainMay 08, 2026

Caris Life Sciences Inc Earnings Call Summary for Q2/2026

  • Q2 revenue hit $263.7M, beating estimates by 10.8%; shares surged 15.56% after-hours on strong clinical volume and pricing power.
  • Full-year revenue guidance raised to $1.03B-$1.04B from $1.00B-$1.02B; adjusted EBITDA of $55.7M marks fifth consecutive positive quarter.
  • Clinical cases reached record 59,200, up 18% YoY; gross margin expanded to 68% from 63% prior year on improved operating leverage.
  • Caris Detect multi-cancer test launched in June with strong demand; company tripling capacity from $1B to $3B annual revenue potential.
  • Q3 pricing guidance set at $3,800-$3,900 per test; MRD products and MI Clarity V2 expected to launch in second half of 2026.
Last Updated: 2026-08-05, 06:08 p/m
Read Full Transcript

Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
-- / 0.01
Revenue / Forecast
263.7M / 238M
EPS Revisions
Last 90 days

CAI Income Statement

Compare CAI to Peers and Sector

Metrics to compare
CAI
Peers
Sector
Relationship
P/E Ratio
58.6x−46.5x−0.4x
PEG Ratio
0.570.580.00
Price/Book
10.4x2.0x2.6x
Price / LTM Sales
6.2x12.8x3.1x
Upside (Analyst Target)
21.6%12.5%47.9%
Fair Value Upside
Unlock−22.7%6.3%Unlock

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
64.76M22.92%1.41B
Other Institutional Investors
117.34M41.52%2.56B
Public Companies & Retail Investors
100.49M35.56%2.19B
Total
282.6M100.00%6.16B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC10.89%30,785,585671,126
Whitney VI, L.P.6.46%18,256,615397,994

People Also Watch

47.79
TBBB
-2.87%
25.91
WRBY
+0.12%
26.980
NAMS
+1.16%
35.74
MDLN
+0.45%
50.050
YPF
+1.21%

FAQ

What Is the Caris Life Sciences (CAI) Stock Price Today?

The Caris Life Sciences stock price today is 21.80 USD.

What Stock Exchange Does Caris Life Sciences Trade On?

Caris Life Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Caris Life Sciences?

The stock symbol for Caris Life Sciences is "CAI."

What Is the Caris Life Sciences Market Cap?

As of today, Caris Life Sciences market cap is 6.16B USD.

What Is Caris Life Sciences's Earnings Per Share (TTM)?

The Caris Life Sciences EPS (TTM) is 0.37.

When Is the Next Caris Life Sciences Earnings Date?

Caris Life Sciences will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is CAI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Caris Life Sciences Stock Split?

Caris Life Sciences has split 0 times.

How Many Employees Does Caris Life Sciences Have?

Caris Life Sciences has 1846 employees.

What is the current trading status of Caris Life Sciences (CAI)?

As of Aug 17, 2026, Caris Life Sciences (CAI) is trading at a price of 21.80 USD, with a previous close of 21.80 USD. The stock has fluctuated within a day range of 21.45 USD to 22.43 USD, while its 52-week range spans from 14.19 USD to 42.50 USD.

What Is Caris Life Sciences (CAI) Price Target According to Analysts?

The average 12-month price target for Caris Life Sciences is 27.00 USD, with a high estimate of 36 USD and a low estimate of 22 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +23.85% Upside potential.

What Is the CAI Premarket Price?

CAI's last pre-market stock price is 22.26 USD. The pre-market share volume is 5,510.00, and the stock has decreased by 0.08, or 0.36%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.